Ligand Pharms Valuation
| LGNXZ Stock | USD 0 0.00 0.00% |
Ligand Pharms seems to be undervalued based on Macroaxis valuation methodology. Our model forecasts the value of Ligand Pharms Glucagon from analyzing the firm fundamentals such as revenue of 277.13 M, and Total Asset of 1.3 B as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and dropping overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Undervalued
Today
Please note that Ligand Pharms' price fluctuation is out of control at this time. Calculation of the real value of Ligand Pharms Glucagon is based on 3 months time horizon. Increasing Ligand Pharms' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Ligand Pharms Glucagon is useful when determining the fair value of the Ligand pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Ligand Pharms. Since Ligand Pharms is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ligand Pink Sheet. However, Ligand Pharms' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0015 | Real 0.003425 | Hype 0.001797 |
The real value of Ligand Pink Sheet, also known as its intrinsic value, is the underlying worth of Ligand Pharms Glucagon Company, which is reflected in its stock price. It is based on Ligand Pharms' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Ligand Pharms' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Ligand Pharms' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Ligand Pharms Glucagon helps investors to forecast how Ligand pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ligand Pharms more accurately as focusing exclusively on Ligand Pharms' fundamentals will not take into account other important factors: Ligand Pharms Total Value Analysis
Ligand Pharms Glucagon is now anticipated to have takeover price of 0 with market capitalization of 0, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Ligand Pharms fundamentals before making investing decisions based on enterprise value of the companyLigand Pharms Investor Information
The company last dividend was issued on the 2nd of July 2018. The quote for Ligand Pharms Glucagon is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC.Ligand Pharms Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Ligand suggests not a very effective usage of assets in April.Ligand Pharms Profitability Analysis
The company reported the revenue of 277.13 M. Net Income was 57.14 M with profit before overhead, payroll, taxes, and interest of 0. Profitability |
| Values |
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Ligand Pharms' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Ligand Pharms and how it compares across the competition.
About Ligand Pharms Valuation
The pink sheet valuation mechanism determines the current worth of Ligand Pharms Glucagon on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Ligand Pharms Glucagon. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Ligand Pharms Glucagon based exclusively on its fundamental and basic technical indicators. By analyzing Ligand Pharms's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Ligand Pharms's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Ligand Pharms. We calculate exposure to Ligand Pharms's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Ligand Pharms's related companies.8 Steps to conduct Ligand Pharms' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Ligand Pharms' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Ligand Pharms' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Ligand Pharms' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Ligand Pharms' revenue streams: Identify Ligand Pharms' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Ligand Pharms' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Ligand Pharms' growth potential: Evaluate Ligand Pharms' management, business model, and growth potential.
- Determine Ligand Pharms' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Ligand Pharms' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Ligand Pharms Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Ligand Pharms does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Retained Earnings | 449.1 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Ligand Pink Sheet analysis
When running Ligand Pharms' price analysis, check to measure Ligand Pharms' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharms is operating at the current time. Most of Ligand Pharms' value examination focuses on studying past and present price action to predict the probability of Ligand Pharms' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharms' price. Additionally, you may evaluate how the addition of Ligand Pharms to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |